Combining pharmacometric models with predictive and prognostic biomarkers for precision therapy in Crohn's disease: A case study of brazikumab.

导出 LinkOut

翻译打印收藏纠错

作者： Nan,Zhang ^[1] ; Ming Liang,Chan ^[1] ; Jing,Li ^[2] ; Philip Z,Brohawn ^[3] ; Bo,Sun ^[2] ; Inna,Vainshtein ^[2] ; Lorin K,Roskos ^[2] ; Raffaella,Faggioni ^[2] ; Rada M,Savic ^[1]

作者单位： Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA. ^[1] Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences (CPSS), R&D, AstraZeneca, South San Francisco, California, USA. ^[2] Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceutical R&D, AstraZeneca, Gaithersburg, Maryland, USA. ^[3]

主题词人类(Humans);Crohn病(Crohn Disease);预后(Prognosis);缓解诱导(Remission Induction);肿瘤蛋白质类(Neoplasm Proteins);抗体, 单克隆(Antibodies, Monoclonal)

DOI 10.1002/psp4.13044

PMID 37691451

发布时间 2024-05-22

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

CPT: pharmacometrics & systems pharmacology

CPT

2023年12卷12期

1945-1959页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Combining pharmacometric models with predictive and prognostic biomarkers for precision therapy in Crohn's disease: A case study of brazikumab.

CPT

相似文献

CPT

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Combining pharmacometric models with predictive and prognostic biomarkers for precision therapy in Crohn's disease: A case study of brazikumab.

CPT

相似文献

CPT

相关期刊

检索历史清除